Takamasa Horio

Life Sciences / Healthcare; Crisis Management / Compliance (Internal Investigations, Global Compliance, Whistleblowing); M&A (M&A / Reorganizations / Capital and Business Alliances, Cross-Border M&A, Private Equity, Start-Ups); Intellectual Property (Intellectual Property Transactions, Intellectual Property Disputes); Corporate Law (Corporate Governance)

Background

Doshisha University (LL.B., 2006); Kyoto University Law School (J.D., 2008); Northwestern University School of Law (LL.M. with honors, 2016); Northwestern University School of Law, Kellogg School of Management (Certificate in Business Administration, 2016); Jenner & Block LLP, Chicago (2016-2017); assigned to the Pharmaceutical Bureau (Compliance and Narcotics Division, Pharmaceutical Evaluation Division, and Medical Device Evaluation Division) of the Ministry of Health, Labour and Welfare as a fixed-term government employee (as Legal Adviser) (2017-2020)

Major Activities

Member of Review Committee for Study Regarding Pharmaceutical Regulations on Medical Equipment Programs Utilizing Artificial Intelligence and Other Advanced Technology⁠, Japan Agency for Medical Research and Development（⁠2020-2022⁠）; Member of Study Group on Countermeasures against Cannabis and Other Drugs⁠, Ministry of Health⁠, Labour and Welfare（⁠2020-2021⁠）; Member of the Advisory Committee (⁠Advisory Committee on Manufacture and Quality Control of Pharmaceutical Products⁠) for Toyama Pharmaceutical Affairs Council (⁠2021⁠); Adviser for The Japan Federation of Medical Devices Associations (⁠2021-⁠); Member of the Toyama Prefecture GMP Inspection Investigative Committee (⁠2021⁠); Member of Legislation Committee⁠, Japan Pharmaceutical Association (⁠2022-⁠); Member of the Board of Experts for the “⁠Consultation Desk for Clinical Research of Medical Equipment⁠,⁠” Japan Association for the Advancement of Medical Equipment (⁠2024-⁠); Member of the Clinical Trial Ethics Review Board⁠, Cancer Institute Hospital Of JFCR (⁠2025-⁠)

admitted in Japan, 2009; Illinois, 2016